Rivaroxaban

Pre-clinicalUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cerebrovascular Stroke

Conditions

Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant, Matrix Metalloproteinases

Trial Timeline

Jan 18, 2019 → Dec 31, 2024

NCT ID

NCT03772457

About Rivaroxaban

Rivaroxaban is a pre-clinical stage product being developed by Bayer for Cerebrovascular Stroke. The current trial status is unknown. This product is registered under clinical trial identifier NCT03772457. Target conditions include Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant.

What happened to similar drugs?

5 of 7 similar drugs in Cerebrovascular Stroke were approved

Approved (5) Terminated (1) Active (1)

🔄donepezil hclEisaiPhase 3

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

❌AbciximabEli LillyPhase 3

✅ticagrelor + ASA + Placebo+ASAAstraZenecaApproved

✅AtorvastatinPfizerApproved

✅Botulinum toxin type A + PlaceboIpsenApproved

✅Atorvastatin 20mgBrain BiotechApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04416048	Phase 2	Terminated	Nov 30, 2020	Jul 20, 2021	COVID-19
NCT04096547	Pre-clinical	UNKNOWN	Sep 25, 2019	Aug 30, 2022	Atrial Fibrillation
NCT03772457	Pre-clinical	UNKNOWN	Jan 18, 2019	Dec 31, 2024	Cerebrovascular Stroke
NCT02387229	Phase 3	Terminated	Mar 1, 2015	May 18, 2024	ATRIAL FIBRILLATION
NCT02116036	Approved	Completed	Sep 1, 2014	Sep 30, 2017	Antiphospholipid Antibody Syndrome
NCT01464450	Phase 1	Completed	Oct 1, 2011	Dec 1, 2011	Pharmacokinetics
NCT01094886	Phase 3	Completed	Mar 1, 2010	Dec 1, 2010	Arthritis

Competing Products

14 competing products in Cerebrovascular Stroke

See all competitors

Product	Company	Stage	Hype Score
YM872 (zonampanel)	Astellas Pharma	Phase 2	35
donepezil hcl	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43
ONO-2506	Ono Pharmaceutical	Phase 2/3	30
Abciximab	Eli Lilly	Phase 3	32
atomoxetine + Stimulants	Eli Lilly	Pre-clinical	26
ticagrelor + ASA + Placebo+ASA	AstraZeneca	Approved	43
Valsartan	Novartis	Pre-clinical	18
Atorvastatin	Pfizer	Approved	43
Darolutamide (BAY1841788) + Enzalutamide	Bayer	Phase 1	26
Botulinum toxin type A + Placebo	Ipsen	Approved	40
Atorvastatin 20mg	Brain Biotech	Approved	40
Autologous bone marrow mononuclear cell transplantation	Brain Biotech	Phase 1	11
Roflumilast Oral Tablet	Brain Biotech	Phase 2	25